365 related articles for article (PubMed ID: 34308311)
1. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
Cardoso R; Graffunder FP; Ternes CMP; Fernandes A; Rocha AV; Fernandes G; Bhatt DL
EClinicalMedicine; 2021 Jun; 36():100933. PubMed ID: 34308311
[TBL] [Abstract][Full Text] [Related]
2. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
Kotit S
Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
[TBL] [Abstract][Full Text] [Related]
3. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Zhou H; Peng W; Li F; Wang Y; Wang B; Ding Y; Lin Q; Zhao Y; Pan G; Wang X
Front Cardiovasc Med; 2022; 9():875327. PubMed ID: 35600478
[TBL] [Abstract][Full Text] [Related]
8. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
9. Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials.
Eraikhuemen N; Leung S; Warren SB; Lazaridis D; Smith CH; Kearson ML; Marcellus V
Am J Cardiovasc Drugs; 2023 Mar; 23(2):113-126. PubMed ID: 36572841
[TBL] [Abstract][Full Text] [Related]
10. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Starr JA; Pinner NA
Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
[TBL] [Abstract][Full Text] [Related]
11. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
[TBL] [Abstract][Full Text] [Related]
12. Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials.
Lin Y; Cai Z; Yuan J; Liu H; Pang X; Chen Q; Tang X; Geng Q; Dong S
Cardiovasc Diabetol; 2022 Nov; 21(1):237. PubMed ID: 36348348
[TBL] [Abstract][Full Text] [Related]
13. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.
Butler J; Usman MS; Khan MS; Greene SJ; Friede T; Vaduganathan M; Filippatos G; Coats AJS; Anker SD
ESC Heart Fail; 2020 Dec; 7(6):3298-3309. PubMed ID: 33586910
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials.
Shoar S; Shah AA; Ikram W; Farooq N; Udoh A; Tabibzadeh E; Khavandi S; Khavandi S
Am J Cardiovasc Dis; 2021; 11(3):262-272. PubMed ID: 34322297
[TBL] [Abstract][Full Text] [Related]
16. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
Vaduganathan M; Docherty KF; Claggett BL; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; McMurray JJV; Solomon SD
Lancet; 2022 Sep; 400(10354):757-767. PubMed ID: 36041474
[TBL] [Abstract][Full Text] [Related]
17. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
;
Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
[TBL] [Abstract][Full Text] [Related]
18. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
[TBL] [Abstract][Full Text] [Related]
19. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.
Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R
ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials.
Adamou A; Chlorogiannis DD; Kyriakoulis IG; Stamatiou I; Koukousaki D; Kardoutsos I; Sagris D; Doehner W; Ntaios G
Intern Emerg Med; 2024 Mar; 19(2):565-573. PubMed ID: 38353880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
